http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013155473-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 |
| filingDate | 2012-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013155473-A |
| titleOfInvention | PHARMACEUTICAL COMBINATION FOR APPLICATION FOR INDUCING LOSS OF BODY WEIGHT IN SUBJECTS WITH TYPE 2 DIABETES OR / AND TO PREVENT A BODY WEIGHT SET IN SUBJECTS WITH TYPE 2 DIABETES |
| abstract | 1. A pharmaceutical combination for use to improve glucose tolerance in subjects with type 2 diabetes, comprising: (a) desProExendin-4 (1-39) -Lys-NH or / and its pharmaceutically acceptable salt, and (b) metformin and / or its a pharmaceutically acceptable salt, wherein the subject to be treated is younger than 50 years old and has a plasma glucose concentration 2 hours after a meal of at least 14 mmol / L. 2. The pharmaceutical combination according to claim 1, wherein the subject to be treated has a glucose fluctuation of at least 2 mmol / L, at least 3 mmol / L, at least 4 mmol / L, or at least 5 mmol / L while the glucose fluctuation is the difference in plasma glucose concentration 2 hours after a meal and plasma glucose concentration 30 minutes before a test meal. 3. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated is obese. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated has a body mass index of at least 30 kg / m. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated is an adult. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated does not receive anti-diabetic treatment. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated has been diagnosed with type 2 diabetes at least 1 year or at least 2 years before starting therapy. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated has an HbA1c value of from about 7 to about 10% .9. Pharmaceutical Comb |
| priorityDate | 2011-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.